However, compensatory signaling through the RAS/RAF/MEK/ERK pathway following tyrosine kinase receptor upregulation or pathway cross-talk can lead to resistance to PI3K inhibitors, particularly in BRAF-mutant melanoma where ERK signaling is enhanced, warranting the need for combination therapy (27–31). This evidence concerns the gene PIK3CA and melanoma.